Back to today’s briefing

Story perspectives

SSRIs Show Promise in Reducing Alzheimer's Tau Pathology

5/31/2025

49 11

Summary

Story summary

A groundbreaking study reveals that selective serotonin reuptake inhibitors (SSRIs) could potentially reduce tau pathology in Alzheimer's patients. In a group of 191 participants, those taking SSRIs exhibited lower levels of phosphorylated tau-181 and improved metabolic function in the dorsal raphe nucleus. Yet, the cognitive outcomes were inconsistent, highlighting the need for further exploration into SSRIs' role in Alzheimer's treatment.

1 of 1

Story summary

A groundbreaking study reveals that selective serotonin reuptake inhibitors (SSRIs) could potentially reduce tau pathology in Alzheimer's patients. In a group of 191 participants, those taking SSRIs exhibited lower levels of phosphorylated tau-181 and improved metabolic function in the dorsal raphe nucleus. Yet, the cognitive outcomes were inconsistent, highlighting the need for further exploration into SSRIs' role in Alzheimer's treatment.